AstraZeneca Reports Q1 2025 Revenue of $13.59 Billion, with China Sales at $1.81 Billion and Enhertu Surging to $1.086 Billion

Apr 29, 2025 14:25 CST Updated 14:25

AstraZeneca

Biopharmaceutical Manufacturer

On April 29, AstraZeneca released its Q1 2025 financial report,Revenue of $13.588 billion, a year-on-year increase of 10%(Calculated at constant exchange rates CER, same below), including product sales revenue of $12.875 billion (+9%). R&D investment was $3.159 billion, a year-on-year increase of 15%.

Source: AstraZeneca 2025 Q1 Financial Report, same as below

By region, the US revenue was $5.646 billion (+10%), accounting for 42% of the total revenue; ChinaAstraZeneca's third largest market after the United States and Europe,Revenue of $1.805 billion in Q1 this year(+5%), accounting for 13% of total revenue.

From the perspective of disease areas, tumors,CVRM（Cardiovascular, Renal and Metabolic Diseases）, Respiratory and Immunology（R&I），Vaccines and Immunotherapy（V&I）Rare diseases contributed $5.643 billion (+13%) to AstraZeneca, respectively.$3.22 billion (+13%),$20.84 billion (+13%),$2.25 billion (-1%),$2.042 billion in revenue.

From the perspective of the product，Farxiga (Dapagliflozin) at $2.057 billionWith an 8% increase in revenue, it continues to firmly hold the top position as AstraZeneca's best-selling drug. Tagrisso (Osimertinib) and Imfinzi (Durvalumab) achieved revenues of $1.679 billion (+8%) and $1.221 billion (+16%), ranking second and third, respectively.

In terms of ADC,GermanyTrastuzumab is the first ADC jointly developed by Daiichi Sankyo and AstraZeneca.Since its launch in December 2019, in just five years, sales reached over $3.4 billion in 2024 and are expected to exceed $4 billion in 2025. The productThe sales figures for the first quarter of this year are as follows:$10.86 billion, growing rapidly.

Datozumab (TROP2 ADC), the second ADC launched through the collaboration between Daiichi Sankyo and AstraZeneca, has successively entered the Japanese, U.S., and European markets since December of last year. According to Daiichi Sankyo's financial report, the product has generated sales of $10 million (1.4 billion yen).